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Abstract: Although the awareness and control of hypertension has increased, only 37% of 
hypertensive patients in the US achieve the conservative goal of 140/90 mmHg. Achieving 
optimal blood pressure (BP) control is the most important single issue in the management of 
hypertension, and in most hypertensive patients, it is diffi cult or impossible to control BP with 
one drug. Blocking two or more BP regulatory systems provides a more effective and more 
physiologic reduction in BP, and current guidelines have recommended the use of combination 
therapy as fi rst-line treatment, or early in the management of hypertension. Fixed combination 
therapy is an effi cacious, relatively safe, and may be cost-effective method of decreasing 
BP in most patients with essential hypertension. Similar to other combinations, fi xed-dose 
combination tablets containing the dihydropyridine calcium channel blocker amlodipine and 
the angiotensin II receptor blocker olmesartan bring together two distinct and complementary 
mechanisms of action, resulting in improved BP control and potential for improved target organ 
protection relative to either class of agent alone.
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Introduction
Hypertension is a highly prevalent condition and an important modifi able risk factor 
for cardiovascular (CV) disease. Hypertension affects nearly 1 in 3 adults in the US, 
with a prevalence of 29.3% in a population 18 years old (Hajjar and Kotchen 2003; 
Ong et al 2007; Rosamond et al 2008), and as many 1.5 billion persons worldwide 
will have hypertension by 2025 (Kearney et al 2005).
Hypertension is the most common risk factor for CV death and disability in both 
developed and developing countries, and control of blood pressure (BP) signifi cantly 
reduces these risks (Turnbull et al 2003; Kearney et al 2005). Observational studies 
have shown that mortality from ischemic heart disease and stroke in persons 40–89 
years of age increases in log linear fashion with increases in both systolic (SBP) and 
diastolic BP (DBP) (Lewington et al 2002). For each increase in SBP of 20 mmHg 
or in DBP of 10 mmHg over the entire range from 115/75 mmHg, there is a twofold 
increase in mortality related to coronary artery disease and stroke.
Although the awareness and control of hypertension have increased, only 37% of 
hypertensive patients in the United States achieve the conservative goal of 140/90 mmHg 
(Ong et al 2007). Achieving optimal BP control is the most important single issue in 
the management of hypertension, and in most hypertensive patients, it is diffi cult or 
impossible to control BP with one drug. For example, in the very large Antihypertensive 
and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) trial less than 
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30% of more than 42,000 participants achieved goal BP 
(140/90 mmHg) on monotherapy (Cushman et al 2002). 
In the Losartan Intervention For Endpoint (LIFE) trial, in 
which treatment to goal (140/90 mmHg) was aggressively 
pursued in 9,000 patients with left ventricular hypertrophy 
(LVH) and an average baseline BP of 175/98 mmHg, 90% 
required more than one antihypertensive agent (Dahlöf et al 
2002). Although participants in the LIFE trial had free medi-
cations and close follow-up, only 49% of patients assigned 
to losartan and 46% assigned to atenolol achieved the BP 
goal (140/90 mmHg).
Based on clinical trials, current guidelines have recom-
mended the use of combination therapy as fi rst-line treatment, 
or early in the management of hypertension in patients with 
comorbidities that require prompt BP reduction. Initial treat-
ment with 2 antihypertensive agents is suggested for persons 
with BP 20/10 mmHg above goal (Figure 1) (Chobanian 
et al 2003; Mancia et al 2007).
Patient adherence
Patient adherence refers to the willingness and ability of an 
individual patient to follow health-related advice, take medi-
cation as prescribed, attend scheduled clinic appointments, 
and complete recommended tests and consultations (Murphy 
and Coster 1997). Poor adherence to medication regimens 
contributes to the practice – outcome gap, in which clinical 
guidelines are implemented but expected benefi ts are not real-
ized. For example, in one study, nonadherence to medication 
was by far the leading cause of hospitalization in a series of 
179 patients admitted to hospital with acute decompensa-
tion of pre-existing heart failure, being implicated in 42% 
of hospital admissions (Michalsen et al 1998). In another 
study of 1,015 outpatients with stable coronary heart disease, 
self-reported medication nonadherence was associated with a 
greater than 2-fold increased rate of subsequent CV events, 
such as coronary heart disease death, myocardial infarction, 
and stroke (Gehi et al 2007).
Multiple medications and complexity of treatment regi-
men are two of the determinants of poor medication adher-
ence. A survey conducted by the National Council on Patient 
Information and Education showed that one-third of patients 
receive at least 2 prescriptions and 10% of patients receive 4 
or more prescriptions after a visit to a primary care physician 
(Dezii 2000). This survey also has estimated that the adher-
ence rate is in the range of 30% for chronic conditions.
There is a clear inverse relationship between complexity 
of the dosing regimen/number of drugs that patients have to 
take and patient adherence. Adherence to antihypertensive 
agents varies inversely with dosing frequency (Sica 1994). 
For example, among 198 Canadian hypertensives randomized 
to diltiazem twice-daily compared with amlodipine once-
daily, those on the once-daily regimen took the medication 
more regularly than those on twice-daily dosing (Leenen et al 
1997). Among 91 diabetic patients using oral antidiabetic 
agents, the adherence rate, defi ned as the percentage of doses 
taken during the observation period, fell from 79% on once-
daily to 38% on 3-times daily dosing (Paes et al 1997).
Adherence to antihypertensive treatment is inversely 
related to achieved BP levels, ie, nonadherent patients tend 
to have higher BP than adherents. In a prospective study of 
347 hypertensive patients, BP levels were compared between 
adherents and nonadherents with antihypertensive treatment 
(Khalil and Elzubier 1997). Patients were considered adher-
ent if the number of pills prescribed or dispensed – the num-
ber of pills missed/number of pills prescribed or dispensed 
for the interval time × 100 was 80%. BP was signifi cantly 
lower in adherent than in nonadherent patients.
Adherence rate is also inversely related to the number 
of drugs given. Patients are more adherent when they take 
a combination as a single tablet than if they are given the 
same drugs as 2 separate pills, even when dosed once daily 
(Neutel 2005). A meta-analysis of 9 studies which compared 
fi xed-dose combinations versus free-drug components of the 
regimen separately for treatment of hypertension (4 studies), 
diabetes (2 studies), tuberculosis (2 studies), and human 
immunodefi ciency virus (HIV) disease (1 study), showed 
that fi xed-dose combinations decreased rate of nonadherence 
by 26% compared with free-drug component regimens 
(Bangalore et al 2007). A subgroup analysis of the four studies 
in hypertension showed that fi xed-dose combinations decreased 
the risk of medication nonadherence by 24% compared with 
free-drug combinations (Figure 2) (Bangalore et al 2007).
Fixed-dose combination therapy is an effi cacious, rela-
tively safe, and possibly cost-effective method of decreas-
ing BP in most patients with essential hypertension (Sica 
2002). Initiating therapy with more than one agent offers the 
potential advantages of achieving BP control more rapidly 
and avoiding dose-related adverse effects of individual drugs 
by producing greater BP reductions at lower doses of the 
component agents. Fixed-dose combinations also have other 
advantages (Table 1) (Lewanczuk and Tobe 2007; Woodham 
and Oparil 2007).
Adherence to antihypertensive treatment increases with 
fi xed-dose combinations (Figure 3). Adherence to a fi xed-
dose combination of the calcium channel blocker (CCB) 
amlodipine with the angiotensin converting-enzyme (ACE) 
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inhibitor benazepril has been compared with adherence to 
free-dose combination therapy of the two agents in a retro-
spective analysis of data obtained from a pharmacy claims 
database in the US (Wanovich and Kerrish 2004). Patients 
who received 2 or more prescriptions for the fi xed-dose 
combination (n = 2,839) or the two components separately 
(n = 3,367) were identifi ed and followed up for an average of 
259 days and 247 days, respectively. Adherence to fi xed-dose 
combination therapy was signifi cantly greater than for free 
combination therapy, 88% vs 69%, respectively. In another 
study, hypertensive subjects receiving once-daily, single-
capsule, fi xed-dose combination of amlodipine – benazepril 
Figure 1 Algorithm for treatment of hypertension. BP, blood pressure. Modifi ed from Chobanian et al (2003).
Lifestyle modifications
Not at goal BP
(<140/90 mmHg or <130/80 mmHg for those with diabetes,
chronic kidney disease or coronary artery disease)
Initial drug choices
Hypertension with
compelling indications
Stage 1 hypertension
(140–159/90–99
mmHg)
Monotherapy with
thiazide-type
diuretics for most
May consider
combination
Stage 2 hypertension
(r 160/100 mmHg)
2-drug combination
for most
Drug(s) for the
compelling
indications
Optimize dosages or add additional drugs until goal
BP is achieved
Consider consultation with hypertension specialist
Not at goal BP
Hypertension without
compelling indications
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demonstrated signifi cantly better medication adherence than 
subjects receiving an ACE and a CCB as separate compo-
nents, 80.8% vs 73.8%, respectively (Taylor and Shoheiber 
2003). The average annual cost of CV-related care per subject 
was also signifi cantly lower in hypertensive patients receiv-
ing the fi xed-dose.
The most important reason for use of combination therapy 
in clinical practice is that combining two antihypertensive 
agents with complementary mechanisms of action produces 
signifi cantly greater BP reducing effi cacy than either of the 
components as monotherapy (Chrysant 1994; Chrysant et al 
2004; Hasebe 2005). As hypertension is multifactorial and 
many pathophysiologic factors contribute to high BP, the 
combination of agents with different (and complementary) 
mechanisms of action provides more complete blockade of 
pressor mechanisms with less activation of counter-regulatory 
mechanisms. For example, diuretics activate the renin-
angiotensin-aldosterone system (RAAS), reduce volume, 
and make BP more angiotensin dependent. Concomitant 
administration of an ACE inhibitor or an angiotensin II 
receptor blocker (ARB) blocks angiotensin II generation 
or action, minimizing the compensatory pressor effect of 
diuretic-induced RAAS activation and producing an additive 
BP-lowering effect.
Combination therapy also improves tolerability by reduc-
ing dose-dependent side effects (clinical or metabolic) of 
individual components. Upward dose titration in an attempt 
to avoid the addition of a second agent often leads to increases 
in dose-dependent side effects, resulting in discontinuation of 
therapy. Appropriate combination therapy can also improve 
tolerability if one component can neutralize the adverse 
effects of the second agent. For example, the tendency for 
thiazides to cause hypokalemia is blunted by concomitant use 
of potassium-sparing diuretics, ACE inhibitors, or ARBs. In 
Figure 2 Effect of fi xed-dose combinations versus free-drug combination on the risk of medication nonadherence in cohort with hypertension. Reprinted from Bangalore S, Kamalakkannan G, 
Parkar S, et al 2007. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120:713–19. Copyright © 2007, with permission from Elsevier.
Table 1 Advantages of fi xed-dose combination therapy
 •  Increased compliance, simplifi ed titration, and convenience 
of use.
 • Potentiation of antihypertensive effects of single compounds.
 • Additive or synergistic effects.
 • Enhancing effect in specifi c populations.
 • Attenuation in adverse events.
 •  Decreases in diuretic-induced metabolic changes with ACE 
inhibitors or ARBs.
 •  Decrease in calcium channel anatagonist-related peripheral 
edema with ACE inhibitors or ARB.
 • Improved overall results, greater BP response, and lower cost.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; BP, blood pressure.
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a prospective 8-week study of 1,346 hypertensive patients, 
the incidence of hypokalemia was lower in those assigned 
to receive valsartan – hydrochlorothiazide (HCTZ) than in 
those assigned to HCTZ monotherapy (Pool et al 2007). 
Further, the peripheral edema caused by the dihydropyridine 
CCB amlodipine is reduced with ARBs or ACE inhibitors 
(Messerli et al 2000; Neutel et al 2005; Philipp et al 2007). 
For example, in a prospective randomized double-blind 
study of 1,079 hypertensive patients who were assigned to 
receive amlodipine/benazepril or amlodipine or nifedipine 
monotherapy, the incidence of edema was 15% in the high-
dose nifedipine group and 24% in the high-dose amlodipine 
group and was greatly reduced in patients treated with any 
dose of combination therapy (1.5%–3.8%) or low-dose CCB 
(4.9%–5.4%) (Messerli et al 2000). In another prospective 
study of 1,911 patients, the incidence of peripheral edema 
was signifi cantly lower in patients randomized to receive 
the ARB valsartan plus amlodipine than in patients treated 
with amlodipine monotherapy (5.4% vs 8.7%, respectively; 
p = 0.014) (Philipp et al 2007).
Overview of currently available 
fi xed combinations
The very earliest outcome trial of antihypertensive therapy, 
the Veteran’s Administration Cooperative Study on Antihy-
pertensive Agents, demonstrated dramatic reductions in CV 
outcomes with a triple combination of HCTZ, reserpine, and 
hydralazine compared with placebo (Veterans Administra-
tion Cooperative Study 1967). Fixed-dose combinations of 
newer antihypertensive drugs have been developed in recent 
years, in response to the realization that most patients require 
multiple antihypertensive agents for BP control (Prisant et al 
1995). The currently available fi xed-combination therapies 
are listed in Table 2.
ACE inhibitor – diuretic or ARB – diuretic combina-
tions are the most commonly used fi xed-dose combination 
antihypertensive agents because of an additive effect on BP 
reduction related to complementary mechanisms of action 
of the components and the favorable vascular, metabolic, 
cardiac, and renoprotective effects of the ACE inhibitors and 
ARBs (Lewis et al 1993; Weir and Dzau 2001; Chobanian 
et al 2003). Randomized controlled clinical trials that com-
pared the combination versus monotherapy with either ACE 
inhibitor or HCTZ have generally demonstrated greater 
BP-lowering effi cacy with low-dose combinations over 
higher-dose monotherapy with either single agent. In a 
representative trial, patients were randomized to 8 weeks of 
placebo, lisinopril 10 mg, HCTZ 12.5 mg, HCTZ 25 mg, or 
combination therapy with lisinopril 10 mg and either HCTZ 
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Figure 3 Medication adherence with combination of amlodipine/benazepril single-
tablet compared to same combination as separate components.
Table 2 Currently available combination antihypertensives in US 
in 2007
ACE inhibitors and diuretics
 Benazepril – HCTZ
 Captopril – HCTZ
 Enalapril – HCTZ
 Lisinopril – HCTZ
 Fosinopril – HCTZ
 Quinapril – HCTZ
 Moexipril – HCTZ
ARBs and diuretics
 Losartan – HCTZ
 Valsartan – HCTZ
 Irbesartan – HCTZ
 Telmisartan – HCTZ
 Olmesartan – HCTZ
 Candesartan – HCTZ
 Eprosartan – HCTZ
Potassium-sparing diuretics and HCTZ
 Amiloride – HCTZ
 Spironolactone – HCTZ
 Triamterene – HCTZ
BBs and diuretics
 Metoprolol – HCTZ
 Timolol – HCTZ
 Atenolol – Chlorthalidone
 Bisoprolol – HCTZ
 Nadolol – Bendrofl umethiazide
 Propranolol – HCTZ
ACE inhibitors and CCB
 Enalapril – Diltiazem
 Benazepril – Amlodipine
 Enalapril – Felodipine
 Trandolapril – Verapamil
ARBs and CCBs
 Valsartan – Amlodipine
 Olmesartan – Amlodipine
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; BB, β-blockers; CCB, calcium-channel blockers; HCTZ, hydrochlorothiazide.
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12.5 mg or 25 mg (Chrysant 1994). Monotherapy with either 
agent lowered DBP by 6–8 mmHg over placebo, and com-
bination therapy produced a further 6–7 mmHg reduction 
in DBP. BP response rate, defi ned as a decrease in DBP of 
10 mmHg or achieving a goal of 90 mmHg, was higher 
with combination therapy (70%–80%) than with lisinopril 
or HCTZ monotherapy (40%–50%).
Similarly, studies of ARB – diuretic combinations have 
demonstrated signifi cantly greater reductions in SBP and 
DBP compared with monotherapy with either individual 
agent. A representative factorial study evaluated the effi cacy 
of regimens that included either olmesartan 10–40 mg a day, 
HCTZ 12.5 or 25 mg a day, placebo, or the combination of 
olmesartam and HCTZ (Chrysant et al 2004). The greatest 
effect on BP was noted in the arm receiving 40 mg of 
olmesartan and 25 mg of HCTZ, in which SBP decreased by 
23.5 mmHg and DBP by 13.7 mmHg more than with placebo 
(Figure 4). The addition of diuretic to placebo or to any dose 
of olmesartan produced an additional BP response compared 
with placebo or olmesartan alone. Control (140/90 mmHg) 
rates were greater in patients taking the highest dose of the 
combined agents than in those taking the highest doses of 
monotherapies.
ACE inhibitor – CCB combinations also have additive 
antihypertensive effects and offer the added advantage of 
minimizing adverse effects of individual components (eg, edema 
with dihydropyridine CCBs). The Anglo-Scandinavian Cardiac 
Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-
BPLA) presented evidence that a CCB – ACE inhibitor 
combination is more effective in lowering BP and reducing risk 
of mortality and major CV events than traditional therapy with 
a β-blocker (BB) – thiazide combination (Dahlöf et al 2005; 
Poulter et al 2005). ASCOT included 19,257 hypertensive 
patients randomly assigned to either amlodipine-based treatment 
(with the option of adding perindopril) or to atenolol-based 
treatment (with the option of adding bendrofl umethiazide). 
BP control was defi ned as 140/90 mmHg in patients without 
diabetes and 130/80 mmHg with diabetes. The CCB – ACE 
inhibitor combination lowered BP by an average of 2.7/1.9 
mmHg more than the BB – diuretic combination throughout the 
5.5 year median follow-up period. Signifi cant reductions in a 
number of outcomes (all-cause mortality, nonfatal myocardial 
infarction, and new-onset diabetes) were noted with CCB – ACE 
inhibitor compared with BB – diuretic. Importantly, by the 
end of the trial only 15% and 9% of participants were taking 
amlodipine or atenolol monotherapy, respectively, providing 
additional evidence for the inadequacy of monotherapy for 
BP control.
Similar to the ACE inhibitor – CCB combination, 
ARB – CCB combinations have showed effi cacy in reducing 
BP. The Nifedipine and Candesartan Combination Study 
(NICE Combi) randomized 258 hypertensive patients to 
receive controlled-release nifedipine 20 mg plus candesartan 
8 mg in combination or up-titration of candesartan 
12 mg monotherapy (Hasebe et al 2005). BP reduction 
was signifi cantly greater in the combination therapy group 
(12.1/8.7) than in the up-titrated monotherapy group (4.1/4.6, 
p  0.0001) after 8 weeks of follow-up. The NICE Combi 
study provides additional evidence that low-dose fixed 
combination therapy is more effective in reducing BP than 
monotherapy in high-dose.
ACE inhibitor – CCB combination therapy has become 
widely used due to high effi cacy in reducing BP and high 
tolerability. Evidence that both CCBs and ACE inhibitors 
have beneficial effects on endothelial function (Taddei 
et al 2000) has also led to the hypothesis that, for the same 
BP effects, an ACE inhibitor – CCB combination may 
have outcome advantages over an ACE inhibitor – diuretic 
combination. Further, it has been hypothesized that the 
neutral metabolic effects of amlodipine, in contrast to the 
adverse metabolic effects of diuretics, translate into better 
clinical outcomes, even when each agent is combined with 
an ACE inhibitor. The latter argument has provided the 
rationale for the Avoiding Cardiovascular events through 
COMbination therapy in Patients Living with Systolic 
Hypertension (ACCOMPLISH) trial, the fi rst randomized 
controlled blinded study to compare prospectively the 
effects of 2 fi xed combinations of antihypertensive drugs, 
benazepril – amlodipine and benazepril – HCTZ on CV 
disease outcomes in high-risk hypertensive patients (Jamerson 
et al 2004). The primary study endpoint is a composite of 
CV mortality and morbidity and the secondary endpoints 
include new onset diabetes, progression of renal disease, and 
hospitalization for congestive heart failure. Early unblinded 
results from 10,704 participants from both treatment groups 
combined have shown higher BP control rates compared with 
previous clinical trials (Jamerson et al 2007). The 6-month 
BP control rate (140/90 mmHg) was 73% in the overall 
trial (78% in the US); 43% of diabetics and 40% of patients 
with renal disease achieved the more aggressive BP goal of 
130/80 mmHg. Serious hypotensive events occurred in only 
1.8%, suggesting that these combinations are appropriate 
and safe for hypertensive patients who are at high-risk. 
Final results of ACCOMPLISH will provide insight into 
whether CCB – RAAS inhibitor combination therapy offers 
advantages over diuretic-RAAS inhibitor combinations in 
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lowering BP, minimizing adverse effects, and preventing 
morbid and mortal CV events.
Amlodipine
Pharmacology
Dihydropyridine CCBs act by decreasing Ca2+ entry to cells 
through the L-type Ca2+ channel (Krum 1997; Messerli 2003). 
Decreased availability of intracellular Ca2+ in arterial smooth 
muscle cells prevents actin and myosin from interacting, 
resulting in vasodilation (Prisant 2005). Dihydropiridine 
CCBs also facilitate natriuresis by increasing renal blood 
fl ow, dilating afferent arterioles, and increasing glomerular 
fi ltration pressure.
Amlodipine is a long-acting third generation 
dihydropyridine CCB that is the most commonly used agent 
in its class for the treatment of hypertension (Abernethy and 
Schwartz 1999; Basile 2004). More than 90% of amlodipine 
is absorbed and 95% of circulating amlodipine is bound to 
plasma proteins. It does not have an extensive hepatic fi rst-
pass metabolism, which contributes to its prolonged effect. 
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Figure 4 Reduction (model fi tted) in seated systolic blood pressure (SBP) (upper panel) and seated diastolic blood pressure (DBP) (lower panel) for 12 groups in the factorial 
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The time to peak effect of amlodipine is 10–14 hours; its 
elimination half-life is 35–45 hours and steady-state plasma 
levels are reached after 7–8 days of consecutive daily dosing 
(Prisant 2005). About 90% of amlodipine is converted to 
inactive metabolites via hepatic metabolism, and 60% of 
the metabolites are excreted in the urine. In patients with 
chronic kidney disease, the pharmacokinetics of amlodipine 
are minimally changed. In hepatic disease, diminished 
systemic clearance may necessitate dosage adjustments. 
Aging slows the metabolism of amlodipine, presumably 
secondary to the accompanying decrease in hepatic blood 
fl ow, sometimes necessitating dosage adjustments in the 
elderly (Prisant 2005; Weir 2008). Amlodipine may cause 
refl ex tachycardia early in the course of therapy or at 
very high doses, but this sympathoexcitatory effect is not 
evident with usual clinical doses or with long term treatment 
(Weir 2008).
Effi cacy and safety
Amlodipine effectively lowers BP and is also effective in 
reducing CV disease outcomes, both morbid and mortal, 
with the exception of heart failure. In the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT), more than 40,000 high risk hypertensive patients 
were randomly assigned to receive chlorthalidone, amlodip-
ine, lisinopril, or doxazosin (ALLHAT 2002). Participants 
were men and women aged 55 years or older who had stage 
1 or stage 2 hypertension with at least 1 additional risk fac-
tor for coronary heart disease events. ALLHAT tested the 
hypothesis that the newer drug classes (CCBs, ACE inhibi-
tors, α-blockers) are superior to the thiazide-like diuretics in 
preventing fatal and nonfatal coronary events. Thus, due to 
the design of the trial, the effects of a RAAS inhibitor-CCB 
combination could not be tested. ALLHAT is the only large 
outcome trial in hypertension that has included a racially/
ethnically diverse patient population (35% Black, 19% His-
panic) and a large (36%) population of diabetics. Amlodipine 
was as effective as chlorthalidone in reducing the primary 
combined endpoint of fatal coronary heart disease or nonfatal 
myocardial infarction. In addition, amlodipine was effective 
in reducing combined coronary heart disease events and end-
stage renal disease. However, incidence of heart failure was 
38% higher in patients assigned to amlodipine than patients 
assigned to chlorthalidone in the absence of concomitant 
RAAS inhibitor therapy in either group. There was no sig-
nifi cant difference in adverse effects between amlodipine and 
chlorthalidone based therapy, refuting previous claims that 
dihydropyridine CCBs precipitate coronary events.
The Valsartan Antihypertensive Long-Term Use 
Evaluation (VALUE) trial compared the effects of amlodipine 
and valsartan as fi rst-line therapy in reducing CV outcomes 
in hypertensive patients at high CV risk (Julius et al 2004). 
Amlodipine treatment was associated with a more prompt and 
robust reduction in BP than valsartan treatment, particularly 
early in the trial when participants were on monotherapy. In 
the study as a whole, amlodipine treatment was associated with 
a signifi cantly greater reduction in the incidence of nonfatal 
myocardial infarction compared with valsartan treatment. 
Subanalysis of VALUE results reported that patients treated 
with amlodipine monotherapy had a 22% higher risk of 
heart failure than those treated with valsartan monotherapy; 
there were no other signifi cant outcome differences (Julius 
et al 2006). These data are consistent with the fi ndings in 
ALLHAT that amlodipine does not prevent heart failure as 
effectively as some other antihypertensive drugs. However, 
data from Prospective Randomized Amlodipine Survival 
Evaluation (PRAISE) study showed that amlodipine does not 
increase CV morbidity or mortality in patients with severe 
heart failure, suggesting that this CCB does not worsen 
established heart failure (Packer et al 1996).
In ASCOT, the amlodipine – perindopril regimen was 
more effective in reducing BP and preventing CV events 
than the atenolol – bendrofl umethiazide regimen (Dahlöf 
et al 2005). BP was, on average, 2.7/1.9 mmHg lower in the 
amlodipine group than in the atenolol group during 5.7 years 
of follow-up. Amlodipine ± perindopril was also superior 
in preventing fatal and nonfatal stroke, total CV events and 
procedures, and all-cause mortality than atenolol ± ben-
drofl umethiazide. Interestingly, the incidence of fatal and 
nonfatal heart failure did not differ between amlodipine- and 
atenolol-based regimens, suggesting that blocking the RAAS 
neutralizes the adverse effects of amlodipine monotherapy. 
By the end of the trial, 85% of patients assigned to amlo-
dipine and 91% of those assigned to atenolol were taking at 
least 2 antihypertensive agents, reinforcing the concept that 
combination therapy is needed to control BP in high risk 
hypertensive patients. There was a signifi cant difference in 
favor of the amlodipine-based regimen in the proportion of 
patients who stopped the trial therapy because of serious 
adverse events.
Amlodipine has been proven effective in decreasing 
left ventricular mass in hypertensive patients. In a 1-year 
prospective study of 59 patients with diastolic hypertension 
who were randomized to lisinopril or amlodipine, amlodipine 
decreased left ventricular mass as effectively as lisinopril 
(–11.0 g/m2 vs –12.6 g/m2, respectively) (Beltman et al 1988). 
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Further, in the Effects of Amlodipine and Lisinopril on Left 
Ventricular Mass and Diastolic Function (ELVERA) trial, 
which compared amlodipine with lisinopril therapy in 166 
elderly patients with hypertension (95–115/160–220 mmHg), 
amlodipine and lisinopril reduced left ventricular mass and 
improved diastolic function to a similar extent after 2 years 
of follow-up (Terpstra et al 2001).
Olmesartan
Pharmacology
ARBs lower BP by selectively blocking the binding 
of angiotensin II to the AT1 receptor in vascular smooth 
muscle and other cell types (Ruddy and Kostis 2005). 
Olmesartan medoxomil, the most recently developed ARB, 
is rapidly and completely bioactivated by ester hydrolysis 
in the gut wall to the pharmacologically active compound 
olmesartan, with peak plasma concentrations achieved 
between 1 and 3 hours and an elimination half-life of 
12–18 hours (Laeis et al 2001; Schwocho and Masonson 
2001). The absolute bioavailability of olmesartan medoxomil 
after oral administration is 26%–28.6%. Steady-state plasma 
concentrations are reached within the fi rst few days, and 
accumulation is not noted on long-term dosing. Olmesartan 
is not metabolized; 35%–50% of the systemically available 
active compound is excreted unchanged in the urine and the 
remainder in the bile. Olmesartan medoxomil has minimal 
or no inhibitory activity on human cytochrome p450 (Laeis 
et al 2001; Schwocho and Masonson 2001). Olmesartan 
has a unique mechanism of binding to the AT1 receptor 
that appears to contribute to its sustained duration of AT1 
receptor blockade (Miura et al 2006, 2008). This involves 
the “double chain domain”, whereby olmesartan binds to 
the receptor at 2 sites, a –OH group and an α-COOH group, 
whereas other ARBs bind only at the –OH group. It has been 
shown that olmesartan produces more sustained inhibition of 
the pressor effects of infused angiotensin than other ARBs in 
normotensive adults, suggesting a more prolonged blockade 
of the AT1 receptor. It has been hypothesized (but not proven) 
that this sustained pressor inhibition is a function of the 
“double chain domain” binding.
Effi cacy and safety
Olmesartan reduces BP rapidly and effectively in hyperten-
sive patients. An analysis of 7 randomized, double-blind, 
placebo-controlled, parallel-group studies compared the 
safety and effi cacy of olmesartan monotherapy with pla-
cebo in patients with essential hypertension (Neutel 2001). 
Olmesartan produced dose-dependent BP reductions in both 
DBP and SBP within 1 week of initiating treatment, and the 
response was nearly maximal within 2 weeks.
At traditionally recommended starting doses, olmesartan 
reduces BP more effectively than other ARBs (Oparil et al 
2005). A 588 patient, multicenter, randomized, double-blind, 
trial that compared once-a-day therapy with the recom-
mended starting doses of losartan, valsartan, and irbesartan 
showed a signifi cantly greater reduction in sitting cuff DBP 
at trough with olmesartan (11.5 mmHg) than with losartan, 
valsartan, and irbesartan (8.2, 7.9, and 9.9 mmHg, respec-
tively, p  0.005 olmesartan vs losartan; p  0.05 olmesartan 
vs valsartan and irbesartan) (Oparil et al 2001). Reductions in 
cuff SBP with the four ARBs had the same numerical trend, 
but differences between treatments were not statistically sig-
nifi cant due to variability in the data. The reduction in mean 
24-hour DBP with olmesartan (8.5 mmHg) was signifi cantly 
greater than reductions with losartan and valsartan (6.2 and 
5.6 mmHg, respectively, p  0.05) and showed a trend toward 
signifi cance compared with the reduction in DBP with irbe-
sartan (7.4 mmHg; p = 0.087). The reduction in mean 24-hour 
SBP with olmesartan (12.5 mmHg) was signifi cantly greater 
than those with losartan and valsartan (9.0 and 8.1 mmHg, 
respectively) and equivalent to the reduction with irbesartan 
(11.3 mmHg). All drugs were well tolerated.
The differences in BP reduction with olmesartan com-
pared with other ARBs are attenuated at higher doses. In an 
12-week, randomized, double-blind, forced titration study, 
723 hypertensive patients were assigned to receive olmesar-
tan, losartan, and valsartan (Giles et al 2007). Patients were 
randomized to olmesartan 20 mg, losartan 50 mg, valsartan 
80 mg, or placebo, all once daily. Doses were titrated to 40, 
100, and 160 mg once daily for olmesartan, losartan, and 
valsartan, respectively, after 4 weeks of treatment. At week 8, 
doses were titrated to 50 mg twice daily for losartan and 
320 mg once daily for valsartan; olmesartan remained at the 
maximum recommended dose of 40 mg once daily. All three 
medications signifi cantly reduced mean seated DBP from 
baseline compared with placebo. At week 8, patients receiv-
ing olmesartan 40 mg once daily had signifi cantly greater 
reductions in mean seated DBP than those receiving losartan 
(–15.2/–12.9 vs –10.9/-9.4 mmHg, respectively, p  0.001); 
there was no signifi cant difference compared with valsartan. 
A signifi cantly greater percentage of patients achieved BP 
goals (140/90 mmHg) with olmesartan compared with 
losartan and valsartan (39.7, 19.8, and 29.0%, respectively, 
p  0.001 vs losartan and p = 0.031 vs valsartan).
Olmesartan has vasoprotective and antiinflammatory 
effects that are unrelated to BP reduction. In the EUropean 
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Trial on Olmesartan and Pravastatin in Inflammation 
and Atherosclerosis (EUTOPIA) study, investigators 
compared the antiinflammatory effects of olmesartan 
alone and with pravastatin in patients with essential 
hypertension and microinflammation (Fliser et al 2004). 
Olmesartan treatment significantly reduced serum levels 
of high-sensitivity C-reactive protein (CRP), high-sensi-
tivity tumor necrosis factor-alpha (TNF-α), interleukin-6 
(IL-6), and monocyte chemotactic protein-1 (MCP-1) 
compared to placebo independently of BP reduction. 
Treatment with pravastatin alone did not significantly 
alter inflammation markers. The Vascular Improvement 
with Olmesartan medoxomil Study (VIOS) tested the 
hypothesis that suppression of RAAS with olmesartan 
reverses abnormal remodeling of resistance vessels and 
has favorable effects on central hemodynamics compared 
to suppression of sympathetic drive with the BB atenolol 
despite equivalent BP control (Smith et al 2007). In the 
presence of nearly physiological BP control, olmesartan 
reversed small resistance vessel remodeling virtually 
back to normal, while atenolol had little to no effect on 
the vascular wall. Further, olmesartan, but not atenolol, 
reduced the augmentation index. Thus, olmesartan has 
favorable effects on surrogate endpoints, but results of 
outcome trials are not yet available.
Olmesartan – amlodipine 
combination
Pharmacology
The pharmacokinetics of the olmesartan – amlodipine combi-
nation are equivalent to the pharmacokinetics of amlodipine 
and olmesartan medoxomil administered separately (Haworth 
et al 2007a; Rohatagi et al 2007; Salazar et al 2007). The 
bioavailability of the combination is well below 100%, and 
is not affected by food (Haworth et al 2007b).
Effi cacy and safety
The combination of olmesartan and amlodipine in a single 
tablet effectively reduces BP and attenuates the adverse 
events of the amlodipine component in hypertensive patients. 
An 8-week, multi-center, double-blind, randomized, placebo-
controlled, parallel-group, factorial study of 1,940 subjects 
with mild to severe hypertension (seated DBP ranging from 
99 to 120 mmHg) compared BP responses with placebo, 
monotherapy with amlodipine 5 mg or 10 mg, with olmes-
artan medoxomil 10, 20, or 40 mg, and combination therapy 
with amlodipine – olmesartan medoxomil at doses of 5/10, 
5/20, 5/40, 10/10, 10/20, and 10/40 mg (Chrysant et al 2007). 
All combinations produced greater mean reductions in BP 
than either drug alone. The highest dose combination, amlo-
dipine 10 mg plus olmesartan 40 mg, reduced SBP by 30.1 
mmHg, a 53% greater reduction than with 10 mg amlodipine 
alone. DBP was reduced by 19 mmHg, compared with 12.7 
mmHg for amlodipine alone. Addition of olmesartan to 
amlodipine decreased the amlodipine-related adverse effects. 
All combinations of amlodipine 10 mg with olmesartan 
demonstrated less peripheral edema than amlodipine 10 mg 
monotherapy.
Patient perspective
Although recent guidelines and advisory statements are 
recommending lower thresholds and goals for antihyper-
tensive treatment, approximately two-thirds of patients 
do not achieve the goals. Population characteristics, 
such as increased life expectancy, higher obesity rates, 
and decreased physical activity, as well as provider 
characteristics, including inadequate attention to SBP 
elevations and the more aggressive BP goals recom-
mended by recent guidelines, are factors that predispose 
to antihypertensive treatment resistance. For patients with 
diffi cult-to-control hypertension, the fi xed-dose combina-
tion offers many advantages, such as convenience of use, 
fewer adverse events, greater antihypertensive potency, 
and lower cost.
Conclusions
Combination therapy is recommended by treatment guide-
lines and has become widely accepted by health care provid-
ers for the therapy of hypertension. Fixed-dose combinations 
provide effective antihypertensive treatment by achieving 
BP goals more frequently, improving patient adherence, and 
decreasing adverse effects.
Use of effective combination therapies blocks two or 
more BP regulatory systems, thus providing more effective 
and more physiologic reduction in BP than most monothera-
pies. Outcomes studies support inclusion of ARBs, such as 
olmesartan, and CCBs, such as amlodipine, in antihyperten-
sive drug regimens.
Disclosures
Dr. Pimenta has no confl icts. Dr. Oparil has received grants-
in-aid from Abbott Laboratories, AstraZeneca, Aventis, 
Biovail, Boehringer Ingelheim, Bristol Myers-Squibb, Forest 
Laboratories, GlaxoSmithKline, Novartis, Merck and Co, 
Pfi zer, Sankyo Pharma, Sanofi -Synthelabo, and Schering-
Plough; has served as consultant for Bristol Myers-Squibb, 
Vascular Health and Risk Management 2008:4(3) 663
Olmesartan-amlodipine combination for hypertension
Daiichi Sankyo, Merck and Co, Novartis, Pfi zer, Sanofi  
Aventis, and The Salt Institute; and is a member of Board of 
Directors for Encysive Pharmaceuticals.
References
Abernethy DR, Schwartz JB. 1999. Calcium-antagonist drugs. N Engl J 
Med, 341:1447–57.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative 
Research Group. The Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial. 2002. Major outcomes in high-risk 
hypertensive patients randomized to angiotensin-converting enzyme 
inhibitor or calcium channel blocker vs diuretic: The Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-
HAT). JAMA, 288:2981–97.
Bangalore S, Kamalakkannan G, Parkar S, et al. 2007. Fixed-dose combi-
nations improve medication compliance: a meta-analysis. Am J Med, 
120:713–9.
Basile J. 2004. The role of existing and newer calcium channel blockers in 
the treatment of hypertension. J Clin Hypertens, 6:621–9.
Beltman FW, Heesen WF, Smit AJ, et al. 1998. Effects of amlodipine and 
lisinopril on left ventricular mass and diastolic function in previously 
untreated patients with mild to moderate diastolic hypertension. Blood 
Press, 7:109–17.
Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh Report of the 
Joint National Committee on prevention, detection, evaluation, and 
treatment of high blood pressure. Hypertension, 42:1206–52.
Chrysant SG. 1994. Antihypertensive effectiveness of low-dose lisinopril-
hydrochlorothiazide combination. Arch Intern Med, 154:737–43.
Chrysant SG, Melino M, Karki S, et al. 2007. A randomized, double-
blind, placebo-controlled factorial study evaluating the effi cacy 
and safety of coadministration of amlodipine besylate (AML) plus 
olmesartan medoxomil (OM) compared to monotherapy in patients 
(PTS) with mild to severe hypertension (HTN) [abstract]. J Clin 
Hypertens, 9:486.
Chrysant SG, Weber MA, Wang AC, et al. 2004. Evaluation of antihy-
pertensive therapy with combination of olmesartan medoxomil and 
hydrochlorothiazide. Am J Hypertens, 17:252–9.
Cushman WC, Ford CE, Cutler JA, et al. 2002. Success and predictors of 
blood pressure control in diverse North American settings: the Anti-
hypertensive Lipid-Lowering treatment to prevent Heart Attack Trial 
(ALLHAT). J Clin Hypertens, 4:393–404.
Dahlöf B, Devereux RB, Kjeldsen SE, et al. 2002. CV morbidity and 
mortality in the Losartan Intervention For Endpoint reduction in 
hypertension study (LIFE): a randomized trial against atenolol. Lancet, 
359:995–1003.
Dahlöf B, Sever PS, Poulter NR, et al. 2005. Prevention of CV events with 
antihypertensive regimen of amlodipine adding perindopril as required 
versus atenolol adding bendrofl umethiazide as required, in the Anglo-
Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm 
(ASCOT-BPLA): a multicenter randomized controlled trial. Lancet, 
366:895–906.
Dezii CM. 2000. Medication noncompliance: what is the problem? Manag 
Care, 9:7–12.
Fliser D, Buchholz K, Haller H, et al. 2004. Antiinfl ammatory effects of 
angiotensin II subtype 1 receptor blockade in hypertensive patients with 
microinfl ammation. Circulation, 110:1103–7.
Gehi AK, Ali S, Na B, et al. 2007. Self-reported medication adherence and 
CV events in patients with stable coronary heart disease: the heart and 
soul study. Arch Inter Med, 167:1798–803.
Giles TD, Oparil S, Silfani TN, et al. 2007. Comparison of increasing doses 
of olmesartan medoxomil, losartan potassium, and valsartan in patients 
with essential hypertension. J Clin Hypertens, 9:187–95.
Hajjar I, Kotchen TA. 2003. Trends in prevalence, awareness, treatment, 
and control of hypertension in the United States 1988–2000. JAMA, 
290:199–206.
Hasebe N, Kikuchi K, for the NICE Combi Study Group. 2005. Controlled-
release nifedipine and candesartan low-dose combination therapy in 
patients with essential hypertension: the NICE Combi (Nifedipine and 
Candesartan Combination) Study. J Hypertens, 23:445–53.
Haworth S, Bathala MS, Lee J, et al. 2007a. A fi xed-dose combination 
of olmesartan medoxomil (OM) and amlodipine besylate (AM) is 
bioequivalent (BEQ) to free combination of the agents [abstract]. Clin 
J Hypertens, 9:A181.
Haworth S, Heyrman R, Bathala MS, et al. 2007b. The bioavailability 
(BAV) of a fi xed-dose combination of olmesartan medoxomil (OM) 
and amlodipine besylate (AM) is unaffected by food [abstract]. Clin 
J Hypertens, 9:A181.
Kearney PM, Whelton M, Reynolds K, et al. 2005. Global burden of hyper-
tension: analysis of worldwide data. Lancet, 365:217–23.
Jamerson K, Bakris GL, Dählof B, et al. 2007. Exceptional early blood pres-
sure control rates: the ACCOMPLISH trial. Blood Press, 16:80–6.
Jamerson KA, Bakris GL, Wun CC, et al. 2004. Rationale and design of the 
avoiding CV events through COMbination therapy in Patients Living 
with Systolic Hypertension (ACCOMPLISH) trial: the fi rst random-
ized controlled trial to compare the clinical outcome effects of fi rst-line 
combination therapies in hypertension. Am J Hypertens, 17:793–801.
Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive 
patients at high cardiovascular risk treated with regimens based 
on valsartan or amlodipine: the VALUE randomised trial. Lancet, 
363:2022–31.
Julius S, Weber MA, Kjeldsen SE, et al. 2006. The Valsartan Antihyperten-
sive Long-Term Use Evaluation (VALUE) trial: outcomes in patients 
receiving monotherapy. Hypertension, 48:385–91.
Khalil SA, Elzubier AG. 1997. Drug compliance among hypertensive 
patients in Tabuk, Saudi Arabia. J Hypertens, 15:561–5.
Krum H. 1997. Critical assessment of calcium antagonists. Aust Fam 
Physician, 26:841–5.
Laeis P, Puchler K, Kiech W. 2001. The pharmacokinetic and metabolic 
profi le of olmesartan medoxomil limits the risk of clinically relevant 
drug interaction. J Hypertens, 19:S21–32.
Leenen FH, Wilson TW, Bolli P, et al. 1997. Patterns of compliance with 
once versus twice daily antihypertensive drug therapy in primary care: 
a randomized clinical trial using electronic monitoring. Can J Cardiol, 
13:914–20.
Lewanczuk R, Tobe SW. 2007. More medications, fewer pills: combina-
tion medications for the treatment of hypertension. Can J Cardiol, 
23:573–6.
Lewington S, Clarke R, Qizilbash N, et al. 2002. Age-specifi c relevance 
of usual blood pressure to vascular mortality: a meta-analysis of indi-
vidual data for one million adults in 61 prospective studies. Lancet, 
360:1903–13.
Lewis EJ, Hunsicker LG, Bain RP, et al. 1993. For the collaborative study 
group: the effect of angiotensin-converting-enzyme inhibitor on diabetic 
nephropaty. N Eng J Med, 329:1456–62.
Mancia G, De Backer G, Dominiczak A, et al. 2007. 2007 Guidelines for 
the management of arterial hypertension: the task force for the manage-
ment of arterial hypertension of the European Society of Hypertension 
(ESH) and of the European Society of Cardiology (ESC). J Hypertens, 
25:1105–87.
Messerli FH. 1993. Evolution of calcium antagonists: past, present, and 
future. Clin Cardiol, 26:II12–6.
Messerli FH, Oparil S, Feng Z. 2000. Comparison of effi cacy and side effects 
of combination therapy of angiotensin-converting enzyme inhibitor 
(benazepril) with calcium antagonist (either nifedipine or amlodipine) 
versus high-dose calcium antagonist monotherapy for systemic hyper-
tension. Am J Cardiol, 86:1182–7.
Michalsen A, Konig G, Thimme W. 1998. Preventable causative factors 
leading to hospital admission with descompensated heart failure. 
Heart, 80:437–41.
Miura S, Fujino M, Hanzawa H, et al. 2006. Molecular mechanism under-
lying inverse agonist of angiotensin II type 1 receptor. J Biol Chem, 
281:19288–95.
Vascular Health and Risk Management 2008:4(3)664
Pimenta and Oparil
Miura S, Kiya Y, Kanazawa T, et al. 2008. Differential bonding interactions 
of inverse agonists of angiotensin II type 1 receptor in stabilizing the 
inactive state. Mol Endocrinol, 22:139–46.
Murphy J, Coster G. 1997. Issues in patient compliance. Drugs, 54:797–800.
Neaton JD, Grimm RH Jr, Prineas RJ, et al. 1993. Treatment of Mild 
Hypertension Study. Final results. Treatment of Mild Hypertension 
Research Group. JAMA, 270:713–24.
Neutel JM. 2001. Clinical studies of CS-866, the newest angiotensin II 
receptor antagonist. Am J Cardiol, 87:37C–43.
Neutel JM. 2005. Fixed combination antihypertensive therapy. In Oparil S, 
Weber MA (eds). Hypertension: a companion to Brenner and Rector’s 
the kidney. 2nd ed. Philadelphia: Elsevier. p 522–9.
Neutel JM, Smith DH, Weber MA, et al. 2005. Effi cacy of combination 
therapy for systolic blood pressure in patients with severe systolic 
hypertension: the Systolic Evaluation of Lotrel Effi cacy and Compara-
tive Therapies (SELECT) study. J Clin Hypertens, 7:641–6.
Ong KL, Cheung BMY, Man YB, et al. 2007. Prevalence, awareness, 
treatment, and control of hypertension among United States adults 
1999–2004. Hypertension, 49:69–75.
Oparil S, Williams D, Chrysant S, et al. 2001. Comparative effi cacy of 
olmesartan, losartan, valsartan and irbesartan in the control of essential 
hypertension. J Clin Hypertens, 3:283–91.
Oparil S, Silfani TN, Walker JF. 2005. Role of angiotensin receptor block-
ers as monotherapy in reaching blood pressure goals. Am J Hypertens, 
18:287–94.
Packer M, O’Connor CM, Ghali KK, et al. 1996. Effect of amlodipine on 
morbidity and mortality in severe chronic heart failure. Prospective 
Randomized Amlodipine Survival Evaluation Study Group. N Engl J 
Med, 335:1107–14.
Paes AH, Bakker A, Soe-Agnie CJ. 1997. Impact of dosage frequency on 
patient compliance. Diabetes Care, 20:1512–7.
Philipp T, Smith TR, Glazer R, et al. 2007. Two multicenter, 8-week, 
randomized, double-blind, placebo-controlled, parallel-group studies 
evaluating the effi cacy and tolerability of amlodipine and valsartan in 
combination and as monotherapy in adult patients with mild to moderate 
essential hypertension. Clin Ther, 29:563–80.
Pool JL, Glazer R, Weinberger M, et al. 2007. Comparison of valsartan/hydro-
chlorothiazide combination therapy at doses up to 320/25 mg versus mono-
therapy: a double-blind, placebo-controlled study followed by long-term 
combination therapy in hypertensive adults. Clin Ther, 29:61–73.
Poulter NR, Wedel H, Dahlöf B, et al. 2005. Role of blood pressure and 
other variables in the differential CV events rates noted in the Anglo-
Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm 
(ASCOT-BPLA). Lancet, 366:907–13.
Prisant LM. 2005. Calcium antagonists. In Oparil S, Weber MA (eds). 
Hypertension: a companion to Brenner and Rector’s the kidney. 2nd 
ed. Philadelphia: Elsevier. p 683–704.
Prisant LM, Weir MR, Papademetriou V, et al. 1995. Low-dose drug 
combination therapy: an alternative fi rst-line approach to hypertension 
treatment. Am Heart J, 130:359–66.
Rohatagi S, Haworth S, Heyrman R, et al. 2007. Low and high doses of a 
fi xed-dose combination of olmesartan medoxomil (OM) and amlodip-
ine besylate (AM) are bioequivalent (BEQ) to free combination of the 
agents [abstract]. Clin J Hypertens, 9:A178.
Rosamond W, Flegal K, Furie K, et al. 2008. Heart disease and stroke 
statistics – 2008 update: a report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation, 
117:e25–146.
Ruddy MC, Kostis JB. 2005. Angiotensin II receptor antagonists. In Oparil 
S, Weber MA (eds). Hypertension: a companion to Brenner and Rector’s 
the kidney. 2nd ed. Philadelphia: Elsevier. p 683–704.
Salazar D, Lee J, Shenouda M, et al. 2007. Lack of pharmacokinetic (PK) 
drug interaction between olmesartan medoxomil (OM) and amlodipine 
besylate (AM) during coadministration [abstract]. Clin J Hypertens, 
9:A180.
Schwocho L, Masonson H. 2001. Pharmacokinetics of CS-866, a new 
angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol, 
41:515–27.
Sica D. 1994. Fixed dose combination antihypertensive drugs. Do they have 
a role in rational therapy? Drugs, 48:16–24.
Sica D. 2002. Rationale for fi xed-dose combination in the treatment of 
hypertension: the cycle repeats. Drugs, 62:443–62.
Smith RD, Yokoyama H, Levy PJ, et al. 2007. Non-invasive hemodynamic 
data reffl ect treatment effects on vascular remodeling [abstract]. J Clin 
Hypertens, 9:A145.
Taddei S, Virdis A, Guiadoni L, et al. 2000. Antihypertensive drugs and 
reversing of endothelial dysfunction in hypertension. Curr Hypertens 
Rep, 2:64–70.
Taylor AA, Shoheiber O. 2003. Adherence to antihypertensive therapy with 
fi xed-dose amlodipine besylate/benazepril HCL versus comparable 
component-based therapy. Congest Heart Fail, 9:324–32.
Terpstra WF, May JF, Smit AJ, et al. 2001. Long-term effects of amlo-
dipine and lisinopril on left ventricular mass and diastolic function in 
elderly, previously untreated hypertensive patients: the ELVERA trial. 
J Hypertens, 19:303–9.
Turnbull F, Blood Pressure Lowering Treatment Trialists’ Colaboration. 
2003. Effects of different blood-pressure-lowering regimens on major 
CV events: results of prospectively-designed overviews of randomised 
trials. Lancet, 362:1527–35.
Veterans Administration Cooperative Study on Antihypertensive Agents. 
1967. Effects of treatment on morbidity in hypertension. Results in 
patients with diastolic blood pressures averaging 115 through 129 mm 
Hg. JAMA, 202:1028–34.
Wanovich R, Kerrish P, Gerbino BP, et al. 2004. Compliance patterns 
of patients treated with 2 separate antihypertensive agents ver-
sus fixed-dose combination therapy [abstract]. Am J Hypertens, 
17:223A.
Weir MR. 2008. Calcium antagonists. In Izzo JL Jr, Sica DA, Black HR 
(eds). Hypertension primer: the essentials of high blood pressure. Basic 
science, population science, and clinical management. 4th ed. Dallas: 
American Heart Association. p 465–9.
Weir MR, Dzau VJ. 2001. The rennin-angiotensin-aldosterone system: 
a specifi c target for hypertension management. Am J Hypertens, 
12:177S–81.
Woodham RM, Oparil S. 2007. Fixed low-dose antihypertensive therapy. 
In Lang and Jones (eds). Comprehensive Hypertension. Philadelphia: 
Mosby Elsevier. p1061–73.
